−Removed: carefully consider the factors discussed in Part I, “Item 1A.
−Removed: Risk Factors”
−Removed: in our Annual Report on Form 10-K for the year
+Added: carefully consider the factors discussed in Part I, “Item 1A.
+Added: Risk Factors” in our Annual Report on Form 10-K for the year
ended December 31, 2020 filed with the SEC on March 31, 2021, which could materially affect our business, financial condition, or future
2 unchanged sentences
to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating
−Removed: Please also see “Special Note Regarding Forward-Looking Statements”
+Added: Please also see “Special Note Regarding Forward-Looking Statements” above.
COVID-19 coronavirus could adversely impact our business, including our clinical trials.
−Removed: We cannot predict the ultimate
−Removed: effects of the Covid-19 pandemic on our business
+Added: We cannot predict the ultimate effects of the
+Added: Covid-19 pandemic on our business
December 2019, a novel strain of coronavirus, COVID-19, was first reported in China.
20 unchanged sentences
of the FDA to accept data from clinical trials in affected geographies outside the United States.
+Added: noted elsewhere in this Report, progress of our commercial launch in Argentina has been delayed due to pandemic factors.
+Added: impact of COVID-19 in Argentina is taxing the nation’s health care system and is, understandably, the main priority of its regulators.
global outbreak of the COVID-19 coronavirus continues to rapidly evolve.
−Removed: The extent to which the COVID-19 coronavirus may impact
−Removed: our business, clinical trials and financial condition will depend on future developments, which are highly uncertain
−Removed: and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak,
−Removed: travel restrictions and social distancing in the United States and other countries, business closures or business disruptions
−Removed: and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.
−Removed: are not able to estimate the effects of the COVID-19 outbreak, if the pandemic continues, it may have a material adverse
−Removed: effect on our results of future operations, financial position, and liquidity.
+Added: The extent to which the COVID-19 coronavirus may impact our
+Added: business, clinical trials and financial condition will depend on future developments, which are highly uncertain and cannot be predicted
+Added: with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social
+Added: distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken
+Added: in the United States and other countries to contain and treat the disease.
+Added: While we are not able to estimate the effects of the COVID-19
+Added: outbreak, if the pandemic continues, it may have a material adverse effect on our results of future operations, financial position, and
+Added: Unregistered Sales of Equity Securities and Use of Proceeds
+Added: Defaults upon Senior Securities
+Added: Mine Safety Disclosures
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.